Dashboard
Manage Tickers

CTMX CytomX Therapeutics, Inc.

Nasdaq cytomx.com


$ 3.58 $ -0.13 (-3.34 %)    

Tuesday, 21-Oct-2025 19:53:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 610.29 $ -0.16 (-0.03 %)
DIA $ 469.10 $ 2.20 (0.47 %)
SPY $ 670.98 $ -0.01 (0 %)
TLT $ 91.99 $ 0.45 (0.49 %)
GLD $ 376.61 $ -25.91 (-6.43 %)
$ 3.615
$ 3.90
$ 3.57 x 100
$ 3.85 x 1,000
$ 3.57 - $ 3.91
$ 0.40 - $ 3.91
2,493,799
na
596.16M
$ 1.51
$ 12.42
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-27-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-24-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-07-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-05-2017 03-31-2017 10-Q
35 03-02-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-07-2016 12-31-2015 10-K
40 11-23-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cytomx-therapeutics-stock-a-deep-dive-into-analyst-perspectives-4-ratings
CytomX Therapeutics Stock: A Deep Dive Int...
10/21/2025 21:01:50

barclays-maintains-overweight-on-cytomx-therapeutics-raises-price-target-to-6
Barclays Maintains Overweight on CytomX Th...
10/21/2025 11:50:23

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/25/2025 21:06:11

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...

cantor-fitzgerald-initiates-coverage-on-cytomx-therapeutics-with-overweight-rating-announces-price-target-of-6
Cantor Fitzgerald Initiates Coverage On Cy...
09/22/2025 12:26:40

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Overweight rating and...

why-serina-therapeutics-shares-are-trading-higher-by-over-25-here-are-20-stocks-moving-premarket
Why Serina Therapeutics Shares Are Trading...
08/26/2025 09:52:07

intuit-workday-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Intuit, Workday And Other Big Stocks Movin...
08/22/2025 08:35:11

cytomx-therapeutics-provides-update-cx-2025-phase-1-study-in-response-to-social-media-posts
CytomX Therapeutics Provides Update Cx-202...
08/13/2025 12:07:40

- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/12/2025 17:07:02

cytomx-therapeutics-focused-on-cx-2051-clinical-date-update-in-q1-2026-and-potential-launch-of-phase-2-study-in-h1-2026
CytomX Therapeutics Focused On CX-2051 Cli...
08/07/2025 21:33:32

cytomx-therapeutics-files-for-mixed-shelf-of-up-to-250m
Cytomx Therapeutics Files For Mixed Shelf ...
08/07/2025 21:26:11

-SECFiling

cytomx-therapeutics-q2-sales-18658m-beat-14725m-estimate
CytomX Therapeutics Q2 Sales $18.658M Beat...
08/07/2025 20:13:53

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly sales of $18.658 million which beat the analyst consensus estimate of $14....

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

this-lexeo-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-thursday
This Lexeo Therapeutics Analyst Begins Cov...
07/31/2025 16:11:53

deep-dive-into-cytomx-therapeutics-stock-analyst-perspectives-4-ratings
Deep Dive Into CytomX Therapeutics Stock: ...
07/31/2025 13:01:12

oppenheimer-initiates-coverage-on-cytomx-therapeutics-with-outperform-rating-announces-price-target-of-7
Oppenheimer Initiates Coverage On CytomX T...
07/31/2025 12:04:50

Oppenheimer analyst Matthew Biegler initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Outperform rating and ann...

heico-monro-abercrombie--fitch-joby-aviation-and-other-big-stocks-moving-higher-on-wednesday
Heico, Monro, Abercrombie & Fitch, Joby Av...
05/28/2025 14:23:37

cytomx-therapeutics-stock-a-deep-dive-into-analyst-perspectives-4-ratings
CytomX Therapeutics Stock: A Deep Dive Int...
05/20/2025 12:01:06

hc-wainwright--co-reiterates-buy-on-cytomx-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Cyto...
05/20/2025 11:13:31

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Buy and maintains $5 pri...

cytomx-therapeutics-doses-first-patient-in-combination-arm-of-phase-1-study-of-cx-801-plus-keytruda-in-patients-with-metastatic-melanoma
CytomX Therapeutics Doses First Patient In...
05/19/2025 12:11:20

piper-sandler-maintains-overweight-on-cytomx-therapeutics-raises-price-target-to-5
Piper Sandler Maintains Overweight on Cyto...
05/15/2025 16:14:00

Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION